SecBot SecBot
SECBOTREPLAY Home › Report › CELC

CELC · Celcuity announced a proposed $400M underwritten public offering of…

Celcuity Inc. · PRESS-RELEASE filed Jun 3, 2026 at 07:19 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Jun 3, 2026 at 07:19 ET

Celcuity announced a proposed $400M underwritten public offering of convertible senior notes due 2032. The offering is dilutive to existing shareholders and signals significant capital needs for a clinical-stage biotech, likely to fund pipeline development. Given the company's pre-revenue status and the large size relative to its $4.5B market cap, this is a notable but not transformative event.

  • Proposed underwritten public offering of $400M aggregate principal amount of convertible senior notes due 2032.
  • Celcuity is a clinical-stage biotechnology company with no approved products or disclosed revenue.
  • The offering represents approximately 8.9% of the company's $4.5B market cap.
  • Convertible notes will likely convert into equity, adding dilution over time.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access